AMEDISYS INC (AMED) Stock Fundamental Analysis
NASDAQ:AMED - Nasdaq - US0234361089 - Common Stock - Currency: USD
Taking everything into account, AMED scores 5 out of 10 in our fundamental rating. AMED was compared to 103 industry peers in the Health Care Providers & Services industry. AMED has an excellent profitability rating, but there are some minor concerns on its financial health. AMED is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
AMED had positive earnings in the past year.
AMED had a positive operating cash flow in the past year.
AMED had positive earnings in 4 of the past 5 years.
In the past 5 years AMED always reported a positive cash flow from operatings.
1.2 Ratios
AMED's Return On Assets of 4.11% is fine compared to the rest of the industry. AMED outperforms 73.79% of its industry peers.
AMED's Return On Equity of 7.49% is fine compared to the rest of the industry. AMED outperforms 67.96% of its industry peers.
Looking at the Return On Invested Capital, with a value of 10.15%, AMED belongs to the top of the industry, outperforming 81.55% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for AMED is in line with the industry average of 9.68%.
The 3 year average ROIC (9.73%) for AMED is below the current ROIC(10.15%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.11% | ||
| ROE | 7.49% | ||
| ROIC | 10.15% |
ROA(3y)2.52%
ROA(5y)6.1%
ROE(3y)4.72%
ROE(5y)11.86%
ROIC(3y)9.73%
ROIC(5y)11.44%
1.3 Margins
AMED has a Profit Margin of 3.79%. This is in the better half of the industry: AMED outperforms 71.84% of its industry peers.
In the last couple of years the Profit Margin of AMED has declined.
AMED has a Operating Margin of 9.17%. This is in the better half of the industry: AMED outperforms 79.61% of its industry peers.
AMED's Operating Margin has been stable in the last couple of years.
AMED has a better Gross Margin (43.37%) than 70.87% of its industry peers.
AMED's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.17% | ||
| PM (TTM) | 3.79% | ||
| GM | 43.37% |
OM growth 3Y-10.17%
OM growth 5Y-0.51%
PM growth 3Y-42.02%
PM growth 5Y-22.26%
GM growth 3Y-1.85%
GM growth 5Y1.03%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), AMED is creating some value.
AMED has more shares outstanding than it did 1 year ago.
The number of shares outstanding for AMED has been increased compared to 5 years ago.
Compared to 1 year ago, AMED has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 4.01 indicates that AMED is not in any danger for bankruptcy at the moment.
AMED's Altman-Z score of 4.01 is fine compared to the rest of the industry. AMED outperforms 73.79% of its industry peers.
The Debt to FCF ratio of AMED is 1.69, which is an excellent value as it means it would take AMED, only 1.69 years of fcf income to pay off all of its debts.
AMED has a Debt to FCF ratio of 1.69. This is amongst the best in the industry. AMED outperforms 83.50% of its industry peers.
A Debt/Equity ratio of 0.28 indicates that AMED is not too dependend on debt financing.
With a decent Debt to Equity ratio value of 0.28, AMED is doing good in the industry, outperforming 64.08% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | 1.69 | ||
| Altman-Z | 4.01 |
ROIC/WACC1.18
WACC8.57%
2.3 Liquidity
AMED has a Current Ratio of 1.29. This is a normal value and indicates that AMED is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.29, AMED perfoms like the industry average, outperforming 40.78% of the companies in the same industry.
AMED has a Quick Ratio of 1.29. This is a normal value and indicates that AMED is financially healthy and should not expect problems in meeting its short term obligations.
AMED has a Quick ratio of 1.29. This is comparable to the rest of the industry: AMED outperforms 46.60% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.29 | ||
| Quick Ratio | 1.29 |
3. Growth
3.1 Past
AMED shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.24%, which is quite good.
AMED shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -0.46% yearly.
The Revenue has been growing slightly by 5.01% in the past year.
Measured over the past years, AMED shows a small growth in Revenue. The Revenue has been growing by 3.73% on average per year.
EPS 1Y (TTM)11.24%
EPS 3Y-10.14%
EPS 5Y-0.46%
EPS Q2Q%16.67%
Revenue 1Y (TTM)5.01%
Revenue growth 3Y1.98%
Revenue growth 5Y3.73%
Sales Q2Q%5.19%
3.2 Future
AMED is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.47% yearly.
AMED is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.95% yearly.
EPS Next Y13.17%
EPS Next 2Y10.6%
EPS Next 3Y6.47%
EPS Next 5YN/A
Revenue Next Year4.17%
Revenue Next 2Y4.73%
Revenue Next 3Y4.95%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 20.74 indicates a rather expensive valuation of AMED.
Based on the Price/Earnings ratio, AMED is valued a bit cheaper than 65.05% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.82, AMED is valued a bit cheaper.
With a Price/Forward Earnings ratio of 18.68, AMED is valued on the expensive side.
AMED's Price/Forward Earnings ratio is in line with the industry average.
AMED is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 36.21, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.74 | ||
| Fwd PE | 18.68 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, AMED is valued a bit cheaper than 60.19% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, AMED is valued a bit cheaper than the industry average as 71.84% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.82 | ||
| EV/EBITDA | 11.94 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of AMED may justify a higher PE ratio.
PEG (NY)1.57
PEG (5Y)N/A
EPS Next 2Y10.6%
EPS Next 3Y6.47%
5. Dividend
5.1 Amount
No dividends for AMED!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
98.51
-0.09 (-0.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners93.07%
Inst Owner Change0.12%
Ins Owners1.89%
Ins Owner Change5.91%
Market Cap3.24B
Analysts53.75
Price Target102.87 (4.43%)
Short Float %6.97%
Short Ratio5.95
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.99%
Min EPS beat(2)-10.15%
Max EPS beat(2)12.12%
EPS beat(4)2
Avg EPS beat(4)-1.2%
Min EPS beat(4)-15.99%
Max EPS beat(4)12.12%
EPS beat(8)3
Avg EPS beat(8)-0.55%
EPS beat(12)6
Avg EPS beat(12)2.46%
EPS beat(16)8
Avg EPS beat(16)2.78%
Revenue beat(2)0
Avg Revenue beat(2)-2.12%
Min Revenue beat(2)-2.2%
Max Revenue beat(2)-2.05%
Revenue beat(4)1
Avg Revenue beat(4)-1.53%
Min Revenue beat(4)-2.2%
Max Revenue beat(4)0.13%
Revenue beat(8)1
Avg Revenue beat(8)-1.99%
Revenue beat(12)1
Avg Revenue beat(12)-2.69%
Revenue beat(16)1
Avg Revenue beat(16)-2.79%
PT rev (1m)0.02%
PT rev (3m)4.88%
EPS NQ rev (1m)-0.3%
EPS NQ rev (3m)-1.54%
EPS NY rev (1m)0.33%
EPS NY rev (3m)1.83%
Revenue NQ rev (1m)0.04%
Revenue NQ rev (3m)-0.32%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.16%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.74 | ||
| Fwd PE | 18.68 | ||
| P/S | 1.37 | ||
| P/FCF | 14.82 | ||
| P/OCF | 14.43 | ||
| P/B | 2.7 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.94 |
EPS(TTM)4.75
EY4.82%
EPS(NY)5.27
Fwd EY5.35%
FCF(TTM)6.65
FCFY6.75%
OCF(TTM)6.83
OCFY6.93%
SpS72.13
BVpS36.48
TBVpS-2.87
PEG (NY)1.57
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.11% | ||
| ROE | 7.49% | ||
| ROCE | 12.85% | ||
| ROIC | 10.15% | ||
| ROICexc | 12.2% | ||
| ROICexgc | 151.22% | ||
| OM | 9.17% | ||
| PM (TTM) | 3.79% | ||
| GM | 43.37% | ||
| FCFM | 9.22% |
ROA(3y)2.52%
ROA(5y)6.1%
ROE(3y)4.72%
ROE(5y)11.86%
ROIC(3y)9.73%
ROIC(5y)11.44%
ROICexc(3y)10.87%
ROICexc(5y)12.42%
ROICexgc(3y)283.58%
ROICexgc(5y)337.19%
ROCE(3y)12.32%
ROCE(5y)14.48%
ROICexcg growth 3Y57.65%
ROICexcg growth 5Y52.31%
ROICexc growth 3Y-5.72%
ROICexc growth 5Y-4.31%
OM growth 3Y-10.17%
OM growth 5Y-0.51%
PM growth 3Y-42.02%
PM growth 5Y-22.26%
GM growth 3Y-1.85%
GM growth 5Y1.03%
F-Score7
Asset Turnover1.09
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | 1.69 | ||
| Debt/EBITDA | 1.2 | ||
| Cap/Depr | 9.64% | ||
| Cap/Sales | 0.25% | ||
| Interest Coverage | 7.77 | ||
| Cash Conversion | 80.59% | ||
| Profit Quality | 243.34% | ||
| Current Ratio | 1.29 | ||
| Quick Ratio | 1.29 | ||
| Altman-Z | 4.01 |
F-Score7
WACC8.57%
ROIC/WACC1.18
Cap/Depr(3y)21.03%
Cap/Depr(5y)20.63%
Cap/Sales(3y)0.4%
Cap/Sales(5y)0.35%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.24%
EPS 3Y-10.14%
EPS 5Y-0.46%
EPS Q2Q%16.67%
EPS Next Y13.17%
EPS Next 2Y10.6%
EPS Next 3Y6.47%
EPS Next 5YN/A
Revenue 1Y (TTM)5.01%
Revenue growth 3Y1.98%
Revenue growth 5Y3.73%
Sales Q2Q%5.19%
Revenue Next Year4.17%
Revenue Next 2Y4.73%
Revenue Next 3Y4.95%
Revenue Next 5YN/A
EBIT growth 1Y18.92%
EBIT growth 3Y-8.39%
EBIT growth 5Y3.2%
EBIT Next Year18.26%
EBIT Next 3Y9.99%
EBIT Next 5YN/A
FCF growth 1Y112.26%
FCF growth 3Y5.56%
FCF growth 5Y2%
OCF growth 1Y102.82%
OCF growth 3Y5.48%
OCF growth 5Y1.88%